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Abstract
One of the earliest pathological features characterizing Alzheimer’s disease (AD) is the loss of dendritic spines.
Among the many factors potentially mediating this loss of neuronal connectivity, the contribution of Rho-GTPases
is of particular interest. This family of proteins has been known for years as a key regulator of actin cytoskeleton
remodeling. More recent insights have indicated how its complex signaling might be triggered also in pathological
conditions. Here, we showed that the Rho-GTPase family member Rac1 levels decreased in the frontal cortex of AD
patients compared to non-demented controls. Also, Rac1 increased in plasma samples of AD patients with Mini-
Mental State Examination < 18 compared to age-matched non demented controls. The use of different
constitutively active peptides allowed us to investigate in vitro Rac1 specific signaling. Its activation increased the
processing of amyloid precursor protein and induced the translocation of SET from the nucleus to the cytoplasm,
resulting in tau hyperphosphorylation at residue pT181. Notably, Rac1 was abnormally activated in the
hippocampus of 6-week-old 3xTg-AD mice. However, the total protein levels decreased at 7-months. A rescue
strategy based on the intranasal administration of Rac1 active peptide at 6.5 months prevented dendritic spine loss.
This data suggests the intriguing possibility of a dual role of Rac1 according to the different stages of the
pathology. In an initial stage, Rac1 deregulation might represent a triggering co-factor due to the direct effect on
Aβ and tau. However, at a later stage of the pathology, it might represent a potential therapeutic target due to the
beneficial effect on spine dynamics.
Introduction
Alzheimer’s disease (AD) is an age-associated disorder,
characterized by the abnormal depositions of hyperpho-
sphorylated tau protein in the form of neurofibrillary
tangles (NFT) and of β-amyloid (Aβ) peptide in the form
of senile plaques (SP). These thoroughly studied hall-
marks are certainly key contributors to the development
of the pathology. However, it is the synaptic and den-
dritic loss, which seems to be the best predictor of the
clinical symptoms. This dysfunction has been extensively
described in early studies [45, 57, 64] and confirmed in
more recent years [17, 42, 59]. Reduction in spine
number correlates well with the degree of memory loss
and cognitive impairment of the patients [16].
Despite the plethora of evidence showing that the
loss of spine stability is associated with AD, the iden-
tification of pathways responsible for this abnormal
disruption is still elusive. In physiological conditions,
spine morpho-dynamics rely on changes of F-actin-rich
cytoskeleton, which are highly regulated by Rho-GTPases
(see reviews [10, 27]). Rho-GTPases maintain the equilib-
rium between actin monomer (G-actin) and filament
(F-actin) pools [18]. This family of proteins comprises of
three main members: Ras-related C3 botulinum toxin
substrate 1 (Rac1), cell division protein 42 (Cdc42), and
Ras homologous member A (RhoA). By switching
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between an active GTP and inactive GDP-bound form,
they convert signals of the postsynaptic receptors into
changes of actin binding proteins, ultimately resulting in
the remodeling of spine shape and density [15, 47]. The
signaling pathway is quite complex: the timely activation
of the 3 proteins is strictly regulated by the association to
several additional regulatory proteins, which are in turn
activated during synaptic transmission or neurotrophic
factor release [47, 58, 65].
As impaired actin cytoskeleton stability [6, 48], includ-
ing the formation of actin rod-like inclusions [33], has
been shown in AD brains, Rho-GTPase signaling
deregulation might contribute to the synaptic degen-
eration observed in the disease [1, 10]. Among the
different members, Rac1 has shown to be connected
to amyloid precursor protein (APP) processing. Stud-
ies on hippocampal primary neurons showed that
Rac1-specific inhibitor decreased APP protein levels
in a concentration-dependent manner by modulating its
transcriptional activity [67]. However, studies examining
the direct connection between Aβ and Rac1 are contra-
dictory, leaving a rather unclear scenario regarding the
potential contribution of the protein to disease-relevant
mechanisms [34, 44, 52].
More puzzling is the connection with the other key
pathological hallmark of the pathology, tau hyperpho-
sphorylation. In the context of cancer and cell migration
studies, Rac1 was shown to directly bind the oncopro-
tein SET [61, 63]. Interestingly for the AD field, SET is
the inhibitor of the protein phosphatase 2A (PP2A), the
major regulator of tau phosphorylation. The laboratory
of Dr. Khalid Iqbal showed extensively how SET abnor-
mally translocated from the nucleus to the cytoplasm in
the brain of AD patients compared to controls [62]. In
the cytosol, SET can directly bind PP2A and decrease its
activity [4]. The pathological relevance of this pathway
was demonstrated by the fact that the overexpression of
SET by adeno-associated viral vectors generated a rat
model of sporadic AD [9, 68, 69].
Here, we provide evidence showing that Rac1 was
altered in fronto-cortical brain lysate and plasma of AD
patients compared to healthy age-matched controls. Im-
portantly, the degree of the alteration in the circulating
Rac1 pool reflected the severity of the cognitive impair-
ment, suggesting a potential role of Rac1 as a biomarker
for AD. In vitro studies on mouse primary cortical
neurons and SH-SY5Y showed that the triggering of
selective Rac1 signaling induced the generation of patho-
genic Aβ fragments and the translocation of SET from
the nucleus to the cytoplasm. This resulted in an
increase of tau phosphorylation (at pT181). Active Rac1
increased in 6-week-old 3xTgAD mouse hippocampus
while the total level decreased at 7 months compared to
controls. Intranasal treatment with a constitutively active
form of the peptide at 6.5 months resulted in a rescue of




Brain samples were provided by the Biobank of the
IRCCS Foundation – Carlo Besta Neurological Institute
and from the Brain Bank of the Department of Path-
ology at Indiana University School of Medicine. We
included 24 brains from AD patients and 12 from
age-matched non-demented controls (Table 1). The
neuropathological diagnosis was performed according to
international guidelines for the assessment of AD [25].
For the plasma samples, the patients considered for
this study underwent clinical and neurological examin-
ation at the MAC Memory Center of the IRCCS Centro
San Giovanni di Dio-Fatebenefratelli, Brescia. Clinical diag-
nosis of AD, MCI was made according to international
guidelines [37, 38, 51]. We included AD (n = 114) and MCI
(n = 47) patients, and age and sex-matched cognitively
healthy controls (CTRL, n = 102). Biological samples were
Table 1 Braak stage and known co-pathologies of the brain
samples in the AD study group
ID Braak stage Co-pathology
AD 1 VI Cerebrovascular disease
AD 2 VI Hemorrage
AD 3 VI –
AD 4 VI Lewy body
AD 5 V Cerebrovascular disease
AD 6 V-VI –
AD 7 VI –
AD 8 III-IV –
AD 9 VI –
AD 10 VI Lewy body
AD 11 VI –
AD 12 III-IV Lewy body
AD 13 IV –
AD 14 III [31] –
AD 15 V-VI Hemorrhage
AD 16 VI –
AD 17 VI Vascular formation
AD 18 VI Cerebrovascular disease
AD 19 VI Cerebrovascular disease
AD 20 V-VI Cerebrovascular disease
AD 21 V-VI Cerebrovascular disease
AD 22 VI Diffuse Lewy body
AD 23 V-VI –
AD 24 IV –
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collected and stored in the Biobank of the IRCCS Centro
San Giovanni di Dio-Fatebenefratelli, Brescia, Italy, after
obtaining informed consent, as approved by the local ethics
committee (approval No. 26/2014). The study was
approved by the local ethics committee (approval No. 03/
2015). Plasma was isolated according to standard proce-
dures. The demographic characteristics of the patients in
the study are shown in Tables 2, 3.
Cell culture and drug/peptide treatments
Primary neuronal cultures (from E18 C57BL/6 J mouse
embryos) and SH-SY5Y neuroblastoma cells were
obtained and cultured as previously described [11]. For
the okadaic acid (OA) treatment, the powder (Sigma-Al-
drich) was dissolved in dimethylsulfoxide (DMSO,
Sigma-Aldrich) at 50 μM concentration as stock solu-
tion. In working solutions, DMSO never exceeded the
concentration of 0.02% and the final OA concentration
was 10 nM. The TAT fusion proteins were prepared as
previously described [12]. For a scheme of the recombin-
ant mutant proteins with all the mutations and a
complete amino acid sequence, see Lorenzetto et al. [30]
For the Leptomycin B (LMB, #9676 Cell Signaling
Technology) treatment, SH-SY5Y cells were differenti-
ated to a mature neuron-like phenotype by retinoic acid
(RA, R2625 Sigma-Aldrich). Cells were seeded on a glass
slide (12 mm Ø), at a density of 103 cells per well, and
RA was added 3 h after plating at a final concentration
of 10 μM in DMEM with 2% FBS and maintained for
10 days. LMB was added to the medium at a final
concentration of 10 pM for 48 h, alone or together with
Tat-Rac1L61F37A or Tat-Rac1WT (1 μM).
The MTT assays were performed 3 or 4 times, in trip-
licate as previously described [11]. The various treat-
ments were compared to the control (untreated cells),
which represented 100% viability.
Animal housing and intranasal delivery
Animal breeding and handling were performed following
a protocol approved by the Animal Care and Use Com-
mittee of the University of Verona (CIRSAL), and autho-
rized by the Italian Ministry of Health, in strict
adherence to the European Communities Council direc-
tives (86/609/EEC). Mice were housed with water and
food ad libitum and with 12 h/12 h light/dark cycle,
under standard environmental conditions (temperature,
humidity). For these studies, female 3xTg-AD mice har-
boring APPswe, PS1M146V, tauP301L transgenes [43], and
age-matched control (C57BL/6) were purchased from
the Jackson laboratory (New Harbor, ME, USA), and
used at 4 different ages: 6 week-, 3, 7, and 16 month-old.
Intranasal administration is a non-invasive method for
delivering therapeutic agents to the central nervous sys-
tem. Animals were randomly assigned to the two treat-
ment groups (PBS solution, Veh; Rac1-L61F37A mutant
peptide solution (100 μM)). Mice were anesthetized
with isofluorane, and a total volume of 16 μl solution
was administered (alternating smaller injections of
4 μl each to the left and to the right nares with
10 min between each administration). Animals were
treated 3 times a week for two weeks, starting from
6.5 months.
ELISA analyses
Brain samples from frontal cortex of AD patients and
age-matched non-demented controls were homogenized
in 9 volumes of 1X PBS using a manual Dounce
homogenizer and centrifuged at 1500 xg for 15 min. Su-
pernatants were collected and the total protein amount
was measured by BCA Protein Assay kit (Pierce).
Blood samples from AD and MCI patients and CTRL
were kept at 4 °C for at least 20 min and then centri-
fuged for 5 min (4 °C, 1,000×g). Plasma was collected
and centrifuged 5 min (4 °C, 1,000×g) after the addition
of the protease inhibitors.
Rac1 and RhoA levels were measured in plasma, in du-
plicate, using commercially available ELISA kits (Human
Ras-Related C3 Botulinum Toxin Substrate 1, RAC1, and
Human Transforming Protein RhoA, MyBioSource).
Rac1-GTP level was assayed using Rac1 Activation
Biochem Kit™ (#BK035, Cytoskeleton). Proteins were
separated by SDS-PAGE and, after blotting, membranes
were probed with anti-Rac1 antibody (mouse anti-Rac1,
1:1000, #05–389, Upstate). GAPDH antibody (rabbit
anti-GAPDH, 1:20000, #G9545, Sigma-Aldrich) was used
as a loading control. All the kits were used according to
the manufacturer’s instructions.
Table 2 Demographic characteristic and plasma Rac1 levels in the four groups
Controls MCI AD MMSE≥18 AD MMSE< 18
No. of subject 102 47 72 42
Gender (% female) 49 64 60 48
Mean age (SD), years 70 (5) 75 (6) 72 (5) 73 (6)








MMSE (SD) 28 (1) 26 (2) 22 (2) 9 (6)
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Immunoprecipitation and immunoproteomic analysis
The mouse brain dissection was performed in a plastic
petri dish on ice, after collecting the whole brain from
the mouse skull. The two cortexes and the hippocampus
were collected, flash frozen in liquid nitrogen, and stored
at − 80 °C until analysis. The whole procedure did not
exceed 5 min to preserve brain integrity.
Brain homogenates (10% weight/volume) were ob-
tained using a micro-pestle on ice in cold lysis buffer
containing: 50 mM Tris-HCl (pH 7.5), 2% Igepal,
10 mM MgCl2, 0.5 M NaCl, 2 mM ethylenediaminetet-
raacetic acid (EDTA), 2 mM ethylene glycol tetraacetic
acid (EGTA), 5 mM benzamidine, 0.5 mM phenyl-
methylsulfonyl fluoride (PMSF), 8 mg/mL pepstatin A
and 20 mg/mL leupeptin, 50 mM b-glycerolphosphate,
100 mM sodium fluoride, 1 mM sodium vanadate,
20 mM sodium pyrophosphate, and 100 nM OA. Ho-
mogenates were clarified by a centrifugation at 4 °C
(10000xG 1 min). After assessment of protein concentra-
tion by Precision red protein quantification assay (Cyto-
skeleton #ADV02), lysates were processed for either
Rac1 activation assay (Cytoskeleton # BK035) or West-
ern Blot. For the Rac1 activation assay, lysates were
diluted to a concentration of 0.5 mg/ml.
The following primary antibodies were used: GluR1
(Anti-GluR, Recombinant rabbit monoclonal antibody,
1:250, 05-855R, Millipore/Merk); Lamin B1 (mouse
monoclonal antibody, 1:1000, B-10:sc-374,015, Santa
Cruz Biotechnology); PSD95 (anti-PSD 95 mouse mono-
clonal antibody, 1:1000, #124 01, Synaptic Systems);
pT181 (Phospho-Tau (Thr181) mouse monoclonal anti-
body (AT270), 1:1000, MN1050 Thermo Fisher Scienific);
Tau-5 (Mouse (monoclonal) Anti-tau (Neurofibrillary
Tangles Marker), clone Tau-5, 1:1000, Invitrogen/Thermo
Fisher Scienific, USA); TuJ1 (rabbit anti-ß-tubulin III anti-
body, 1:2500, T2200 Sigma-Aldrich).
Primary cortical neurons were seeded into 6-well
plates, at a density of 9,5 × 105 cells per well. Following
treatments, cells were washed 1× in Tris-buffered saline
(TBS), then lysed and scraped with 50 μl of pre-warmed
Laemmli buffer and boiled for 10 min. The cell lysate
was assayed for protein using the Bradford method
(Sigma-Aldrich). The lysates were separated using a 4–
12% Bis-Tris gels (Novex pre-cast gel, Invitrogen) and
transferred to 0.45 μm nitrocellulose membrane (Invitro-
gen) for probing with antibodies. Blots were blocked for
1 h at room temperature in 1X Odyssey blocking buffer
(TBS) and incubated with primary antibodies overnight
in Odyssey blocking buffer (TBS) plus 0.1% Tween-20 at
4 °C. Then the membranes were washed 3 × 10 min in
TBST (Tween-20 TBS) at room temperature, followed
by incubation with secondary antibody conjugated to
IRDye diluted in Odyssey blocking buffer (TBS) plus
0.1% Tween-20 for 1 h at room temperature. Blots were
washed 2 × 10 min in TBST, 1 × 10 min in TBS and visu-
alized with Odyssey Infrared Imaging System.
Levels of total tau and tau phosphorylation at each
specific site were determined by using phosphorylation-
dependent and site-specific tau antibodies from Invitro-
gen (rabbit anti-tau (pS262) phosphospecific antibody,
1:1000 for WB and 1:100 IF, #44-750G; mouse anti-tau,
1:1000, #AHB0042; rabbit anti-tau (pS202) phosphospe-
cific antibody 1:1000 for WB and 1:100 IF, #44779G).
The pan-Actin antibody (mouse anti-actin, 1:2500,
#MAB1501, Millipore or rabbit anti-actin, 1:2500,
#A2066, Sigma-Aldrich) was used as a loading control.
Primary antibodies were detected using anti-mouse
IRDye 800 (1:2500; Li-Cor) or anti-rabbit Alexa Flour
680 (1:5000; Invitrogen). Blots were scanned and subse-
quently quantified using the Odyssey Imaging System
(Li-Cor) by quantifying fluorescent signals as Integrated
Intensities (I.I. K Counts) using the Odyssey Infrared
Imaging System, Application Version 1.2 software. After
background subtraction, ratios were calculated for each
antibody against the pan-actin loading control using I.I.
K Counts. The respective antibody to pan-actin ratio
was then used to calculate phosphorylated protein to
total protein ratio.
The subcellular fractionation on primary cortical neu-
rons was performed as previously described [74]. For
these experiments, 5-6 × 106 neurons were seeded. The
membrane fraction was not quantified but directly sus-
pended in 15 μl of sample buffer and loaded on the gel.
Surface-enhanced laser desorption/ionization time-of-
flight mass spectrometry (SELDI TOF MS)
Immunoproteomic analyses of Aβ isoforms were per-
formed as previously described with minor modifications
Table 3 Demographic characteristic and plasma RhoA levels in the four groups
Controls MCI AD MMSE≥18 AD MMSE< 18
No. of subjects 83 45 47 27
Gender (% female) 52 64 58 41
Mean age (SD), years 70 (5) 75 (6) 72 (5) 73 (5)








MMSE (SD) 28 (1) 26 (2) 22 (2) 8 (7)
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[2]. Briefly, 3 μl of the specific monoclonal human anti-
bodies (mAbs) 4G8 (anti-Aβ17–24) + 6E10 (anti-Aβ1–16)
(BioLegend, San Diego, CA, USA) at the total mAbs
concentration of 0.125 mg/ml (concentration of each
mAbs was 0.0625 mg/ml), were incubated in a humidity
chamber for 3 h at room temperature (RT) to allow
covalent binding to the PS20 ProteinChip Array
(Bio-Rad, Laboratories, Inc.). Unreacted sites were
blocked with Tris-HCl 0.5 M, pH 8 in a humid chamber
at RT for 1 h. Each spot was washed first 3 times with
PBS containing 0.5% (v/v) Triton X-100 and then twice
with PBS. The spots were coated with 5 μl of cell lysate
and incubated in a humid chamber at 4 °C overnight.
Each spot was washed first 3 times with PBS containing
0.1% (v/v) Triton X-100, twice with PBS, and finally with
deionized water. One microliter of α-ciano-4-hydroxy
cinnamic acid (CHCA, Bio-Rad Laboratories, Inc.) was
added to each spot. Mass identification was made using
the ProteinChip SELDI System, Enterprise Edition
(Bio-Rad Laboratories, Inc.). The analysis was performed
with mass focus FM5500 and laser energy E1500.
Golgi staining and spine count
Animals were sacrificed by terminal anaesthesia with
2,2,2-Tribromoethanol (ip dose of 0,8 g/kg body weight;
T48402, Sigma-Aldrich, Germany), and intracardially
perfused with 0.9% saline solution added with 0.5% hep-
arin (H3393, Sigma-Aldrich) to remove blood, followed
by 4% paraformaldehyde buffered pH 7, to fix brain
tissue. Brains were impregnated in 50 fold volume of
staining solution, containing 1% HgCl2 (Sigma-Aldrich,
n°7,487,947, Germany), 1% K2Cr2O7 (Sigma-Aldrich)
and 1% K2CrO4 (Sigma-Aldrich), and stored at room
temperature for 2 weeks in the dark.
Brain sections (80 to 100 μm thickness) were obtained
using a vibratome (Leica VT1200, Leica Biosystems,
Germany). Sections were placed in a mixture consisting
of 1 part Developer Replenisher solution (GBX n°
3,101,508, Carestream Dental) and 2 parts Milli-Q water
for 5 min, rinsed in Milli-Q water for 5 min, placed in a
mixture consisting of 1 part Fixer Replenisher solution
(GBX n° 3,101,557, Carestream Dental) and two parts
Milli-Q water for 15 min, and then rinsed again in
Milli-Q water for 5 min. Sections were then dehydrated
in 60, 80 and 100% ethanol 2 min each, cleared in 100%
xylene for 2 min and then mounted in Eukitt (03989
Sigma-Aldrich). Dendrites and spines of 4 sub regions of
the cortex (primary motor cortex, secondary motor
cortex, posterior parietal area and visual cortex) were
imaged by a 100X oil objectives using Olympus BX63
microscope (Olympus Corporation, Japan) and acquired
by Neurolucida 64-Bit software (MBF Bioscience, USA).
Dendritic spines were manually counted scrolling along
the z-stack (0.35 μm) of acquired images, and tagging
spines using the multi-point selection tool of ImageJ
1.47v software (NIH, USA). The dendritic length was de-
termined using the ImageJ software segmented line tool.
Immunostaining and confocal analysis
Immunocytochemistry and image acquisition was
performed as previously described [11]. The following
primary antibodies were used: anti-active Rac1 (1:1000,
#26903, NewEast), pan-axonal neurofilament marker
(1:1000, #SMI-312R, Covance), rhodamine phalloidin
(1:40, #R415, Thermo Fisher Scientific), Aβ17–24 (1:200,
4G8; #SIG-39200, Covance), anti-map2 (1:500, #M9942,
Sigma-Aldrich), anti-SET (I2PP2A; 1:50, #sc-25,564,
Santa Cruz Biotechnology), site-specific tau antibodies
were purchased from Invitrogen (1:100, #44779G).
Aβ1–42 oligomer preparation and dot-blot
The preparation of Aβ1− 42 synthetic oligomers was
performed according to a previously described protocol
[32]. The supernatant with Aβ1–42 oligomers was
assayed for protein content using the Bradford kit
(Sigma-Aldrich). The oligomerization of Aβ1–42 was
checked by dot blotting using two different antibodies:
6E10 (beta amyloid antibody; #SIG-39320, Covance) and
A11 (anti-oligomer antibody; #AHB0052, Invitrogen).
0.1 to 1 μg of each oligomeric preparation were applied
on a nitrocellulose membrane and allowed to air dry.
The membrane was then washed with TBS for 5 min
and blocked with Odyssey Blocking Buffer (Li-Cor,
#FE3092750000) for 1 h at room temperature. The
membranes were then incubated overnight at 4 °C with
6E10 (1:2000) or the conformation dependent antibody
A11 (1:500) in Odyssey Blocking Buffer with 0.1%
Tween-20. Following 3 10-min washes, the blot was incu-
bated with secondary antibody (anti-mouse IRDye 800,
1:2500 (Li-Cor) or anti-rabbit Alexa Flour 680, 1:5000
(Invitrogen)) for 1 h at room temperature, washed again
and scanned on Odyssey Imaging System (Li-Cor).
Regulatory context of Rac1 and AD by bioinformatics
tools
The role of Rac1 in the AD was investigated starting
from the genes related to the disease through GWAS
(Genome Wide Association Studies). The GWAS Cata-
log [70] allowed collecting 720 genes statistically linked
to the pathology. In order to reconstruct a network
connecting the selected genes, including others likely
involved in the process, we started from ANAT [3].
ANAT is a bioinformatics tool to chart molecular path-
ways including direct high confidence interactors to con-
nect all the input genes. SET and PP2A were added to
the list. Of the GWAS list, ANAT did not recognize 269
genes. The resulting network was enriched by ANAT
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with 182 high confidence interactors connecting GWAS
nodes, including Rac1.
Statistical analysis
Data were analysed with Prism 5 (GraphPad Software).
Statistical significant differences are reported as *p <
0.05, **p < 0.01, and ***p < 0.001. The correlation of
plasma Rac1 with MMSE was performed using the
Spearman’s correlation procedure with SPSS 20.0 soft-
ware for Windows (IBM). The sample size and the used
statistical tests are indicated in Table 4.
Results
Rac1 protein levels are altered in human AD fronto-
cortical brain and plasma samples
To investigate the role of Rac1 in the pathogenesis of
AD, fronto-cortical brain homogenates from 24 neuro-
pathologically confirmed AD patients and 12 age-matched
non-demented controls were analysed. Rac1 levels de-
creased in AD brains as compared to controls (Fig. 1a).
We also evaluated Rac1 protein levels in the plasma of
114 patients affected by AD, 47 subjects with mild cogni-
tive impairment (MCI), and 102 sex and age-matched
non-demented controls. To investigate the link between
Rac1 and cognitive decline, a correlation analysis was
performed between Rac1 levels and the Mini-Mental State
Examination (MMSE) in AD: Rac1 plasma levels were
negatively correlated with MMSE score (r = − 0.208; p =
0.026). We stratified AD patients based on their MMSE
score (AD patients with MMSE< 18, n = 42; AD patients
with MMSE≥18, n = 72). Rac1 levels significantly in-
creased in the plasma of the AD patients with MMSE< 18
compared to controls (p = 0.0002), MCI (p = 0.045), and
the AD group with MMSE≥18 (p = 0.0051) (Kruskal-Wal-
lis followed by Dunn’s multiple comparison test) (Fig. 1b).
No alterations were detected in RhoA plasma levels in AD
patients and MCI subjects (AD MMSE≥18 n = 47; AD
MMSE< 18 n = 27; MCI n = 45; CTRL 83; p = 0.104
Kruskal-Wallis test) (Fig. 1c).
Rac1 perturbation affects APP metabolism
To modulate Rac1 activity, we generated TAT-Rac1
mutant proteins. These mutants contained a sequence
coding for TAT, derived from the 86-amino acid transac-
tivation protein involved in HIV replication, which al-
lows the internalization of the protein into the cell. The
produced proteins were: (i) Rac1-WT, which contained
the wild type sequence of the protein; (ii) Rac1-L61F37A
and Rac1-L61Y40C, two double mutants with a point
mutation, which tonically activated the protein (Q61L,
Table 4 Sample size and performed statistical analysis
Figure Number Experiment Test Sample size (n) P value
Fig. 1a Rac1 AD human brain Mann Whitney 12, 24 0.028
Fig. 1b Rac1 human AD plasma Kruskal-Wallis
Dunn’s test
102, 47, 72, 42 0.0005
CTRL vs AD MMSE< 18 p = 0.0002; MCI vs AD
MMSE< 18 p = 0.045; AD MMSE≥18 vs AD
MMSE< 18p = 0.0051;
Fig. 3b SET/GluR1 Two-tailed One
sample t test
10,10,10,6,6 CTRL vs Rac1-WT p = 0.039
CTRL vs Rac1-L61F37A, p = 0.037
Fig. 3d pT181/GAPDH Two-tailed One
sample t test
9, 7, 7,3,3 CTRL vs Rac1-WT p = 0.023; CTRL vs Rac1-L61F37A,
p = 0.014
Fig. 3d pT181/Tau5 Two-tailed One
sample t test
9, 7, 7,3,3 CTRL vs Rac1-L61F37A, p = 0.045;
Fig. 5b Hippocampus 6 weeks
Rac1GTP/Rac1
Student t test 4, 4 0.044
Fig. 5c Cortex 7 months Rac1/
GAPDH
Student t test 6, 6 0.005
Fig. 6a PSD95/Tuj1 One-way Anova
Turkey’s MC
8, 9, 8 0.0064
C57 + Veh vs 3xTgAD + Veh *
3xTgAD + Veh vs 3xTgAD + Rac1 *
Fig. 6d Spine density One-way Anova
Turkey’s MC
4, 4, 4 0.0061
C57 + Veh vs 3xTgAD + Veh *
3xTgAD + Veh vs 3xTgAD + Rac1 **
Additional file 1: Figure S2A Aβ toxicity Two-tailed One
sample t test
4, 4, 4 Aβ0.1 μM 0.0044
Aβ0.5 μM 0.0088
Aβ1μM 0.0414
Additional file 1: Figure S4C 3 h OA Two-Tailed paired
t test
6, 6 0.003
Additional file 1: Figure S4C 6 h OA Two-Tailed paired
t test
4, 4 0.038
*p < 0.05; **p < 0.01
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abbreviated in L61), and a second point mutation (F37A
or Y40C), which conferred selectivity to the downstream
signalling delivery [28]; (iii) Rac1-N17, a dominant nega-
tive (DN) mutant with a single point mutation (T17 N,
abbreviated as N17).
The TAT trojan sequence efficiently allowed the
internalization of the proteins in primary cortical neu-
rons. Confocal pictures showed that TAT-GFP was inter-
nalized within 1 h after the treatment (Additional file 1:
Figure S1A, B). Optical sectioning showed GFP-rich
endosome-like structures in the cytoplasm. TAT-GFP
signal was also evident in live cells imaged 1 h after the
treatment (Additional file 1: Figure S1C). GFP fluores-
cence was found both in the somas as well as in neur-
ites. We also checked, with MTT assay, whether the
mutant peptides were toxic in primary cortical neurons
(Additional file 1: Figure S1D). After 24 h treatment with
2 μM concentration, no toxic effect was observed.
Mature cortical neurons were then treated for 24 h with
1 μM constitutively active (CA) double mutants
(Rac1-L61F37A or Rac1-L61Y40C), Rac1-WT, or
Rac1-DN and stained for F-actin to verify that the pep-
tides were active (Fig. 2a). Both CA mutants increased
F-actin reactivity compared to controls, Rac1-WT, and
Rac1 DN. Rac1-DN reduced F-actin levels as expected.
Staining against 4G8 antibody showed that both CA
mutants enhanced the immunoreactivity of Aβ and/or
its precursor compared to controls, Rac1-WT, and
Rac1-DN (Fig. 2a). The second mutation of the CA
proteins, F37A or Y40C, did not exert any differential
effect, indicating that the observed effect on Aβ metab-
olism is dependent on the Q61L mutation, which the
double mutants had in common. To determine which
Aβ isoform was increasingly generated after the Rac1
peptide treatments, we performed immunoproteomic
analysis, using surface-enhanced laser desorption/
ionization time of flight mass spectrometry (SELDI-TOF
MS). Human SH-SY5Y neuroblastoma cells were treated
with TAT-Rac1 mutant proteins or vehicle: the lysate
analysis revealed the presence of two main Aβ pep-
tides, Aβ1–42 and Aβ11–42 pyr, after Rac1-L61F37A
treatment (Fig. 2b).
To evaluate the directionality of the signalling, we also
checked whether Aβ administration was able to
modulate Rac1. We used synthetic Aβ1–42, which we
allowed to aggregate at 4 °C for 12 h. To test Aβ1–42 tox-
icity, an MTT assay was performed (Additional file 1:
Figure S2A). Mature cortical neurons, cultured for
10 days in vitro (DIV), were incubated for 24 h with
different Aβ1–42 concentrations, ranging from 0.1 μM to
1 μM. The preparation induced a significant toxicity at
0.1, 0.5, and 1 μM. A dot-blot assay verified the presence
of a detectable oligomeric population, using two
different antibodies: 6E10 and A11 (Additional file 1:
Figure S2B). 6E10 is reactive to the amino acid residues
1–16 of Aβ. It is sequence-specific and recognizes both
fibrillar and oligomeric forms as well as the precursor
form. A11 antibody selectively recognizes amino acid
sequence-independent oligomers but does not recognize
monomers or mature fibers. All Aβ1–42 samples were
6E10 and A11 positive, confirming that the preparations
contained oligomers (representative image of the
dot-blot assay).
Primary cortical neurons were treated with 0.1 μM
Aβ1–42 at different time points: 1 h, 3 h, 6 h or 24 h.
After treatments, cells were fixed and immunostained
against the active form of Rac1 protein (Rac1-GTP),
neurofilaments, and F-actin. After 0.1 μM Aβ1–42 ad-
ministration, no differences were observed in Rac1 acti-
vation or localization in all the time points analysed.
Fig. 1 Rac1 is altered in AD brain and plasma samples. a Rac1 (ng/mg of protein) was measured in brain homogenates from CTRL subjects and
AD patients. b Rac1 (ng/ml of protein) was measured in plasma samples from CTRL subjects, MCI, and AD patients (MMSE≥18 and MMSE< 18).
c RhoA (pg/ml of protein) was measured in plasma samples from CTRL subjects, MCI, and AD patients. The data represented are mean ± SEM
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From the images acquired, F-actin seemed also not
affected by the treatment (Additional file 1: Figure S2C).
A few clots were observed along the neurites in the
neurofilament staining after Aβ1–42 administration, at
both concentrations, confirming the toxicity measured
with the MTT assay. These findings indicate that the
interference with Rac1 signalling promotes an increased
APP processing.
Rac1 perturbation affects SET translocation and results in
tau hyperphosphorylation
Next, we evaluated whether Rac1 mutant peptides were
able to interfere with tau phosphorylation. Neurons
treated for 24 h with TAT-Rac1 mutants were stained
against SET. SET, which is normally localized in the
nucleus, translocated to the cytoplasm in AD brains. Its
translocation from the nucleus to the cytoplasm was
shown in AD temporal cortex and hippocampus, com-
pared to age-matched controls [62]. Interestingly, the
administration of both Rac1-WT and CA mutants was
able to elicit the translocation of SET from the nucleus
to the neurites (Fig. 3a). These results indicate that the
protein itself is sufficient to induce SET translocation.
To quantitative confirm this observation, we performed
subcellular fractionation to purify the membranous and
nuclear fractions. SET concentration in the membrane
fraction significantly increased after Rac1-L61F37A and
Rac1-WT treatments, while no change was observed in
the nuclear fraction (Fig. 3b, c). Controls experiments to
ensure the successful enrichment of the 2 fractions were
Fig. 2 Rac1 mutant peptides interfere with APP metabolism. a Primary cortical neurons treated between DIV11 and DIV14 with Rac1 mutant
peptides. After 24 h, cells were stained to visualize of F-actin, APP and Aβ (4G8), and dendrites (MAP2). The increase in F-actin fluorescence was
considered as a sign of Rac1 activation. These representative images were obtained from one of four independent experiments. Scale bar 30
μm. b Representative spectra of Aβ isoforms from SH-SY5Y cell lysates treated with TAT-Rac1 mutant proteins or vehicle (n = 2 experiments in
triplicate). Peak intensity is expressed in μA (μAmpere). 3400 and 4500 are m/z reference values expressed in Dalton in the spectrum scale (m/z
for Aβ 11–42pyr is 3325 Da, m/z for Aβ 1–42 is 4520 Da)
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performed in SH-SH5Y cells (Additional file 1: Figure S3).
The abundancy of Lamin B was checked in the membrane
fraction and the levels of GluR1 were assessed in the nu-
clear fraction. To check whether SET translocation re-
sulted in an increased tau phosphorylation, cortical
neurons were treated for 48 h with the peptides. We chose
pT181 phospho-site as this is one of the major AD abnor-
mally hyperphosphorylated sites regulated by PPA [66].
pT181/Tau5 was significantly increased after treatment
with Rac1-L61F37A compared to vehicle treated cells
(Fig. 3d, e). The use of a nuclear transporter inhibitor
(LMB) reduced SET translocation from the nucleus to
the membrane in SH-SY5Y when Rac1 peptides where
administered. This impeded the increase in tau phos-
phorylation (Fig. 4).
As for Aβ, we checked whether tau-induced hyperpho-
sphorylation altered Rac1 activation. We used okadaic
acid (OA), a synthetic inhibitor of PP2A and PP1, which
Fig. 3 Rac1 mutant peptides induce tau hyperphosphorylation mediated by SET translocation. a Primary cortical neurons treated between DIV11
and DIV14 with Rac1 mutant peptides. After 24 h, cells were fixed and stained to visualize SET, dendrites (MAP2), and nuclei (DAPI). These
representative images were obtained from one of three independent experiments. Scale bar 10 μm. b-c Representative blots and densitometry
of subcellular fractionation indicating the levels of SET in the membrane (SET/GluR1) and nuclear fractions (SET/LaminB) in the same conditions
as in A. 15 μg of protein lysate were loaded for the nuclear fraction. Due to the low yield, the membrane fraction was not quantified. d-e
Representative blots and corresponding quantification of tau pT181 phosphorylation and Tau-5 normalized against GAPDH levels, and pT181/
Tau5. ~ 7 μg of protein lysate were loaded
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is a well-known tool to study AD pathology in vitro [46].
The evaluation of tau phosphorylation was performed
for two of the main phosphorylated epitopes, pS262 and
pS202 (Additional file 1: Figure S4A). Immunostaining
after 6 h from OA treatment showed an enhanced tau
immunoreactivity against both sites compared to the
vehicle treated cells, with a pronounced accumulation in
the somatodendritic compartment. The increased ratio
pS262/tau was also detected via Western Blot at both
time points (Additional file 1: Figure S4B, C). Neurons
were also treated with 10 nM OA for 3 h or 6 h, and
then analysed for Rac1-GTP by pull down assay.
Rac1-GTP pull down assay showed no difference in the
levels of activated proteins between OA treatment and
control (Additional file 1: Figure S4D-E). In addition, the
total expression of the protein was unchanged between
the conditions. Overall, this data establishes a new direct
pathway in which Rac1 induces SET translocation and,
consequently, increases tau phosphorylation.
Rac1 is biphasically altered in 3xTg-AD mice
We investigated whether the reduced Rac1 expression
observed in post-mortem AD brains was also recapitu-
lated in a mouse model of familial AD. The 3xTg-AD
model was selected. Pull-down assay for Rac1 and
Rac1-GTP was performed to evaluate Rac1 levels and
activation in the cortex and hippocampus of control
(C57BL/6 J) and 3xTg-AD mice. We first checked in
young animals, at 6 weeks, and found increased ratio
Rac1-GTP/Rac1 in the hippocampus of 3xTg-AD mice
compared to age-matched controls (Fig. 5a, b). We next
evaluated how the levels of the protein changed over
time at 3, 7, and 16 months. The analysis revealed a sta-
tistically significant decrease in total Rac1 in the cortex
Fig. 4 The nuclear transporter inhibitor LMB blocks Rac1-induced translocation of SET. SH-SY5Y cells at 10 days of RA differentiation were treated
with Rac1-WT and Rac1-L61F37A, with or without LMB in order to block Rac1-peptide mediated SET translocation. After 48 h, cells were fixed and
stained against pT181 tau epitope (green), SET (magenta), F-actin (red), and DAPI (blue) was used to visualize nuclei. Representative images show
that, in control condition SET expression is restricted to the nucleus. After Rac1-WT and Rac1-L61F37A treatments, SET presence is observed also
outside cell nuclei, whereas SET translocation doesn’t occur when LMB is added together with Rac1 mutant treatments. In the same way, tau
phosphorylation at the epitope pT181 is decreased in presence of LMB. Scale bar 25 μm
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of 3xTg-AD mice at 7-month-old compared to the con-
trols. These findings suggest an abnormal activation of
Rac1 at a very early stage of the pathology. This is
followed by a decrease of the total level of the protein at
a later stage, 7 months, when the cognitive impairment
starts to become apparent according to published behav-
ioral studies [60].
Rac1-L61F37A mutant peptide rescues spine loss in 3xTg-
AD mice
Since Rac1 decreased in 7-month-old 3xTg-AD mice, we
administered Rac1-L61F37A to evaluate its potential
effect in ameliorating the known synaptic impairments
[5]. We evaluated Rac1-L61F37A effect on the expres-
sion levels of PSD95 by Western Blot (Fig. 6a, b). Three
experimental groups of animals were tested: C57BL/6 J
mice treated with vehicle, 3xTg-AD mice treated with
vehicle, and 3xTg-AD mice treated with Rac1-L61F37A
(n = 7–9 animals per group). We observed a significant
increase of the post-synaptic marker PSD95 in cortical
homogenate of 7-month-old 3xTg-AD mice compared
to controls. Importantly, after Rac1-L61F37A intranasal
treatment, PSD95 levels normalized back to the control
levels.
In order to analyze in more details the effect of
Rac1-L61F37A mutant treatment, we evaluated the spine
density in the 3 different groups. A total mean number
of 5056 ± 1158.04 spines per animal were counted on
mean dendrite length of 3903.49 ± 888.59 μm per ani-
mal, from 12 animals. Neuronal dendrites were acquired
from four different cortical areas (primary motor cortex,
premotor motor cortex, posterior parietal area and visual
cortex) in each animal: C57BL/6 J treated with vehicle
(N = 4), 3xTg-AD treated with vehicle (N = 4) and
3xTg-AD treated with Rac1-L61F37A (N = 4). 3xTg-AD
mice showed a significant decrease in cortical spine
Fig. 5 Rac1 is altered in 3xTg-AD mice. a, c Representative blots of active and total Rac1 protein levels in homogenates of 3xTg-AD mice and
age-matched control mice. b, d Quantification of Rac1 protein activation (ratio between Rac1-GTP level and total Rac1), and total Rac1 level
(total Rac1 on GAPDH ratio), at the 4 time points (6 weeks: C57BL/6 J n = 6, 3xTG-AD n = 6; 3 months: C57BL/6 J n = 4, 3xTG-AD n = 4; 7 months:
C57BL/6 J N = 7, 3xTG-AD N = 7; 16 months: C57BL/6 J n = 5, 3xTG-AD n = 5). Box and whiskers graphs represent boxes as min to max values,
whiskers as standard errors and means as black lines
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density at 7-month-old respect to control mice (Fig. 6c-d).
Rac1-L61F37A intranasal treatment in 3xTg-AD increased
significantly spine density respect to age-match vehicle-
treated mice, restoring spine density at the same level of
control mice. This data indicates the beneficial effect
of timely activating Rac1 signaling to reverse spine
and synaptic abnormalities in a disease-relevant ani-
mal model.
Pathways analysis indicates the interactome connecting
Rac1 to tau and APP
To further characterize functional interactions between
Rac1 and AD relevant proteins we performed ANAT
analysis (Fig. 7a). In the resulting network, Rac1 is con-
nected to the GWAS identified genes PAK2 [23], CHN2
[19], and IQGAP2 [76]. PAK2 is a well know Rac1 acti-
vator, CHN2 is an inhibitor upon EGF receptor stimula-
tion in fibroblast-like cell lines cells [14], and IQGAP2
modulates Rac1 activity [13]. These proteins are all
involved in cytoskeleton reorganization [21].
To deepen the analysis and to expand interactomic
consistency to the network, the list of 720 GWAS identi-
fied genes, plus SET, PP2A and the 182 high confidence
interactors were submitted to STRING. Of the 269
GWAS genes ANAT did not recognize, STRING recog-
nized only 20, confirming the set of GWAS genes of
interest. The interactions of Rac1 with PAK2, IQGAP2,
and CHN2 were confirmed.
The neighborhood of Rac1, PP2A, and SET was
selected from the STRING interactome. As recom-
mended by STRING for higher confidence, we kept
edges with a “STRING combined score” greater or equal
to 0.7. The resulting network of 113 genes included also
APP and TAU. The 113 set of genes were analyzed with
ClueGO [7] for a Gene Ontology biological process (BP)
evaluation. The first 10 BP classes sorted by number of
interested genes resulting from the analysis contain
between 81 and 31 genes and 4 of them are
cytoskeleton-related: “adherens junction assembly” (47
genes), positive regulation of protein complex assembly
(43 genes), dendritic spine development (34 genes) and
stress fiber assembly (31 genes).
To increase the resolution of the analysis, we calcu-
lated the shortest paths connecting Rac1, SET, PP2A,
and APP or tau. According to STRING results, these
proteins are connected through CDK5 and HSP90AA1
Fig. 6 Rac1 administration rescued dendritic impairment. a Representative immunoblots and (b) densitometry of PSD95 were normalized on Tuj1
in cortical homogenates of control mice (C57BL/6 J treated with vehicle) and 3xTg-AD mice treated with vehicle or with Rac1-L61F37A mutant
peptide (100 μM) at 7 months old. Box and whiskers graphs represent boxes as min to max values, whiskers as standard errors and means as
black lines. 10 μg of protein lysate were loaded. c Representative Golgi-cox stained dendrite portions with spines and (d) quantification of spine
density (numbers of spine per μm of dendrite length) in the three condition analyzed (C57BL/6 J treated with vehicle: 1.32 ± 0.05 spines/μm;
3xTg-AD treated with vehicle: 1.17 ± 0.02 spines/μm; and 3xTg-AD treated with vehicle: 1.39 ± 0.03 spines/μm). The data represented
are mean ± SEM
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(HSP90A), both added by ANAT to the genes set to
build a possible high confidence interactome (Fig. 7b).
CDK5 is related to several of the aforementioned pro-
teins. HSP90A was recently identified as a promising
AD treatment target [8] and a HSP90A knockout has
been associated with Rac1 down regulation [20]. It also
interferes with PP2A mediated AKT phosphorylation
with implications for AD [35].
CDK5 silencing has a Rac1-mediated neuroprotective
effect [54]. SET is required for the stimulatory effect on
the CDK5 region p35(nck5a) and CDK5 phosphorylates
APP and TAU [26, 29], and it has been suggested that
PP2A might act in functional association with GSK3 in
tau hyperphosphorylation [53].
Discussion
Members of the Rho-GTPase family have been previ-
ously connected to pathogenic events contributing to
synaptic deficits in AD. Our data describes a putative
pathway in which Rac1 is up-stream and timely elicits
the alterations of AD relevant proteins. The selective
activation of Rac1 signalling enhanced Aβ levels and
promoted SET translocation from the nucleus to the
plasma membrane. The directionality of this alteration
was confirmed as Aβ administration and tau-induced
hyperphosphorylation did not perturb Rac1 cellular dis-
tribution or activation. At the same time, Rac1 increased
in young 3xTg-AD mice and later decreased at 7 months.
At this latter time point, the intranasal administration of
Fig. 7 Rac1 is linked to PP2A in protein network analysis. a ANAT network starting from the AD GWAS genes plus SET and PP2A (in green)
leading to the addition of high-confidence connecting genes (in purple). b Rac1, SET, PP2A shortest paths to either APP or Tau according to the
STRING network based on GWAS AD plus ANAT high confidence interactors genes. Edges score opacity mapping STRING experimental score
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Rac1 active peptide restored spine loss. This indicates
that the involvement of Rac1 in AD pathological cascade
of events is rather complex. The contribution of Rac1 to
these apparently contradicting pathways might be
explained with the tight spatiotemporal regulation of the
Rho-GTPases. Previous studies showing contrasting data
on the levels of Rac1 in AD versus age-matched controls
might be reconsidered in this light. Rac1 was reported to
be increased [49], or decreased [36] in AD autoptic brain
samples. A closer look into the pathological diagnoses of
the mentioned studies shows that Rac1 increased when
patients with mild AD were selected [49], meanwhile it
decreased in samples with NTF stage V or VI [36]
because of the extensive neuronal death. In the present
study, we found a reduction of Rac1 protein levels in
human AD brain. This decrease was accompanied by an
increased protein plasma levels in AD patients with the
most severe cognitive decline (MMSE < 18). In addition,
Rac1 plasma levels weakly correlated with the cognitive
decline in AD, thus suggesting that this protein might
represent a marker of AD disease progression: further
investigation are mandatories to confirm these prelimin-
ary results. At this stage, therapeutic intervention boost-
ing Rac1 signalling to support spine maintenance might
represent an interesting option. 3xTg-AD mice treated
for 2 weeks at 6.5 months with Rac1-L61F37A showed a
rescue of spine deficits. Both male and female 3xTg-AD
mice showed a subtle deficit in spatial learning and
memory exactly at 6.5 months of age [60], this under-
lying the spine impairment. Rac1-L61F37A peptide was
previously shown to boost cell survival and regeneration
after optic nerve crush by the activation of the Pak\ME-
K\Erk pathway [30]. The protective effect might also be
ascribed to the release of neurotrophic factors as activa-
tion of Erk1/2 resulted in the secretion of endogenous
CNTF [40]. Importantly, intranasal treatment with
Rac1-L61F37A did not significantly interfere with tau
phosphorylation and APP processing when administered
in 3xTg-AD (data not shown). Rac1- L61F37A also
normalized the levels of PSD95 proteins in 3xTg-AD
compared to 3xTg-AD treated with vehicle. It was previ-
ously reported that PSD95 decreased in 3xTg-AD
7 month-old animals [55]. One of the reasons for this
discrepancy might lie in the different loading controls
used (Tuj1 in this study versus actin in Revilla et al.).
Since we administered an actin modulating protein, Tuj1
seemed a better choice. Moreover, many papers have de-
scribed how AD impairs actin stability [48] and its levels
might change over the course of the pathology.
The pathway analysis offered a high-level view of the
pathways connecting Rac1 to AD relevant proteins and
highlighted the strong interaction between Rac1 and tau
through SET and PP2A. The use of mutant peptides
allowed us to better dissect Rac1 signaling, which is
executed by several effectors. In these mutants, the L61
mutation, which tonically activated the protein, was
coupled to a second mutation (F37A or Y40C) that gave
signal specificity [30]. The Y40C blocked the binding to
PAK and JNK mediated pathways meanwhile, F37A acti-
vated them. The specific effect of Rac1-L61F37A on tau
hyperphosphorylation might be mediated by the effector
protein PAK. Rac1-induced PAK activation has been shown
to activate p38MAPK [75], which phosphorylates tau [72].
The reduction of PP2A activity via SET has been shown
to affect APP regulation [24]. Coherently, we observed that
Rac1-L61F37A was also the most effective mutant in deter-
mining an increase of Aβ fragments 11–42pyr and 1–42.
Overexpression of both C and N terminals of SET in rats
determined Aβ accumulation starting from 4-month old
rats [9]. When we tested whether Rac1 could be altered fol-
lowing Aβ administration, we could not observe any im-
pairment. Other studies used synthetic Aβ peptide and
showed a consequent Rac1 activation. However, in these
studies, the used Aβ concentration was in the μM range
(above 1 μM) [34, 39]. Concentrations higher than 1 μM
have been defined by many as “supraphysiological” [22] and
the data obtained thus require careful consideration.
Despite the use of Rac1 mutant peptides, which allowed
different signaling cascades to be triggered, they do not
provide insights into the kinetic of the activation. As
already proposed [50], Rho-GTPases alteration needs to
be studied with tools allowing to follow their spatiotempo-
ral dynamics. The different functions of Rac1 suggest a
highly controlled regulation, which is also dependent on
the cellular compartment. In this regard, new imaging
tools based on sophisticated fluorescent biosensors can
help to resolve the dynamics of these proteins, which are
activated on a micrometer length and sub-minute time
scales [41, 71, 73]. These tools might highlight even more
subtle defects in either their compartmentalization or
crosstalk between the family members.
Additional studies are clearly necessary to further un-
ravel this intricate signaling. Elucidating the molecular
mechanisms underlying the loss of spines is certainly es-
sential for the development of disease-modifying thera-
peutics. Moreover, the possibility of further investigating
Rho-GTPase members as potential indicator of disease
progression for AD in plasma represents an interesting
option. We showed here that Rac1 increased in AD pa-
tients with MMSE< 18 and, in a recent work, that Cdc42
decreased in fronto-temporal dementia patients [56].
Conclusion
Rac1 might have a role in AD as a triggering co-factor,
participating both to Aβ and tau alteration. However, at
a later stage of the pathology, it might represent a poten-
tial therapeutic target due to its beneficial effect on den-
dritic spine dynamics.
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Additional file
Additional file 1: Figure S1. Rac1 mutant peptides have high
penetration due to the TAT sequence. (A-C) Representative confocal
images of cortical neurons treated at DIV3 with different concentrations
of TAT-GFP: 5 μM (A), 10 μM (B, C). After treatment, cells were fixed and
stained for visualization of dendrites (MAP2) and nuclei (DAPI). Confocal
analysis showed that TAT-GFP was internalized (single plane), also in live
cells directly imaged 1h after treatment. Scale bars 10 μm. (D) MTT assay
on primary cortical neurons after 24h from the administration of 2 μM
Rac1 mutant peptides. The cell viability is expressed as % as compared to
control. The data represented are mean ±SEM of four independent exper-
iments, each done in triplicate. Figure S2. Aβ1-42 administration does not
interfere with Rac1 localization or activation. (A) MTT assay on primary
cortical neurons after 24h Aβ1-42 treatment at the indicated concentra-
tions The Aβ peptide suspension was incubated 12h at 4°C prior treat-
ment. The cell viability is expressed as % as compared to control. The
data represented are mean ±SEM of four independent experiments, each
done in triplicate. One-sample t test to a hypothetical mean of 100% was
performed. (B) Representative dot-blot analysis of Aβ1-42 preparations
with 6E10 and A11 antibodies. The protein concentration was 0.12 μg for
6E10 and 0.72 μg for A11 (C) Representative confocal images of primary
cortical neurons treated with 0.1 μM Aβ1-42 between DIV11 and DIV14.
Cells were stained against Rac1-GTP, F-actin, and neurofilament. Scale
bars 30 μm. Figure S3. Efficacy of the subcellular fractionation. Represen-
tative blots of the subcellular fractionation experiments showing the
levels of GluR1, LaminB, and SET in the membrane and nuclear fractions
of SH-SY5Y cells. Four independent samples were assessed for the 2 frac-
tions. Figure S4. Tau induced hyperphosphorylation does not alter Rac1
levels or activation. (A) Representative confocal pictures of mature cortical
neurons treated with 10nM OA for 6h and immunostained against pS262
tau. Scale bar 30 μm. (B-C) Tau pS262 phosphorylation was analysed by
western blot after 3 and 6h from OA administration. The data repre-
sented are mean with SEM of four or six independent experiments (3h
treatment n=6, 6h treatment n=4). (D-E) Rac1-GTP pull done assay was
performed after 3 and 6h from OA administration. The data represented
are mean with SEM of three independent experiments. ns, not significant.
Asterisks indicate unspecific bands. (DOCX 3215 kb)
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